References
- Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
- Marcus R, Imrie K, Solal-Celigny P, Catalano J V, Dmoszynska A, Raposo J C, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579–4586
- Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2004; 104: 3064–3071
- Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89: 753–754
- Kalac M KS, Kardum-Skelin I, Planinc-Peraica A, Siftar Z, Jaksić B. The disappearance of CD20 positive lymphocytes in the pleural effusion after intrapleural application of rituximab. Acta Med Croatica 2007; 61: 425–427
- Crysandt M NB, Das M, Engelbertz V, Bendel M, Galm O, Osieka R, Jost E. Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol 2007; 79: 546–549
- Schmidt H H, Renner H, Linkesch W. Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL. Haematologica 2004; 89: ECR39
- Fink-Puches R, Wolf I H, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005; 52: 847–853
- Roguedas A M, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. Br J Dermatol 2005; 152: 541–544
- Kerl K, Prins C, Saurat J H, French L E. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 2006; 155: 1197–1200
- Paul T, Radny P, Krober S M, Paul A, Blaheta H J, Garbe C. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 2001; 144: 1239–1243
- Kyrtsonis M C, Siakantaris M P, Kalpadakis C, Dimopoulou M N, Vassilakopoulos T P, Kontopidou F N, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol 2006; 77: 300–303